Concert Genetics
Nicole Magdziarz has a diverse work experience in the healthcare industry. Nicole is currently serving as the Vice President of Precision Therapy Solutions at Concert Genetics. Nicole'sprevious role was as a Senior Product Director, Oncology at Optum. Nicole also worked at New Century Health, where they held multiple positions including Associate Director of Product Management, Clinical Product Manager, Clinical Nurse Educator, and Utilization Management. Prior to that, they were an RN at Scottsdale Healthcare, where they provided patient care in the Oncology/Medical-Surgical unit. Nicole has also worked as an Oncology Case Manager at American Health Holding and as a Clinical Instructor at Scottsdale Community College. Nicole started their career as an Infusion Nurse at Scottsdale Medical Specialists, specializing in chemotherapy administration.
Nicole Magdziarz's education history includes several academic achievements in the field of nursing. In 2002 to 2004, they attended Mesa Community College, where they obtained an Associate of Applied Science in Nursing. Nicole then went on to the University of Phoenix from 2005 to 2007 and earned a Bachelor of Science in Nursing. Later, in 2009 to 2010, they pursued a Master of Science in Nursing from the University of Phoenix.
In 2018 to 2019, Nicole pursued a Health Care Innovation Post-Graduate Certificate from Arizona State University. Additionally, in 2019, they obtained a Certificate in Healthcare Innovation from Arizona State University's Edson College of Nursing and Health Innovation.
Nicole Magdziarz has also obtained several certifications to enhance their skills and knowledge in nursing. In June 2009, they became an Oncology Certified Nurse (OCN®) and obtained the same certification from the Oncology Nursing Certification Corporation. Nicole also became a Certified Medical-Surgical Registered Nurse (CMSRN) in October 2009, certified by the Academy of Medical-Surgical Nurses (AMSN) and the Medical-Surgical Nursing Certification Board (MSNCB). Additionally, they hold a Chemotherapy and Biotherapy Certified credential from the Oncology Nursing Society, although the specific date of obtaining this certification is not provided.
This person is not in any offices
Concert Genetics
Genetic testing is the lynchpin of precision medicine, but the rapid pace of change in the market makes it enormously complex. Today, there are more than 75,000 unique genetic testing products on the market, and an average of 10 new products are added each day. This growth confounds the processes through which tests are ordered, resulted, billed and reimbursed. Founded in 2010 with a vision to simplify this complexity, Concert Genetics (formerly NextGxDx, Inc.) launched as a healthcare technology company dedicated to streamlining the genetic test selection, ordering, payment and management for clinicians, hospitals, laboratories and health plans. With a leading team of clinicians, researchers, data scientists and software engineers, Concert Genetics launched its proprietary solutions to enable end-to-end genetic testing management, from searching and comparing testing products, to tracking orders and results, to payment integrity and forecasting trends in pricing and utilization. Today, stakeholders across the healthcare system turn to Concert Genetics to better understand and navigate the rapid transformation to precision medicine that is underway.